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Abstract
AIM
To investigate changes in spleen stiffness measur-
ements (SSMs) and other non-invasive tests (NITs) 
after treatment with direct-acting antivirals (DAAs) 
and identify predictors of SSM change after sustained 
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ORIGINAL ARTICLE
Spleen stiffness mirrors changes in portal hypertension 
after successful interferon-free therapy in chronic-hepatitis 
C virus patients
Retrospective Cohort Study
Federico Ravaioli, Antonio Colecchia, Elton Dajti, Giovanni Marasco, Luigina Vanessa Alemanni, Mariarosa 
Tamè, Francesco Azzaroli, Stefano Brillanti, Giuseppe Mazzella, Davide Festi
virological response (SVR). 
METHODS
We retrospectively analysed 146 advanced-chronic liver 
disease (ACLD) patients treated with DAA with available 
paired SSM at baseline and SVR24. Liver stiffness (LSM), 
spleen diameter (SD), platelet count (PLT) and liver 
stiffness-spleen diameter to platelet ratio score(LSPS) 
were also investigated. LSM ≥ 21 kPa was used as a 
cut-off to rule-in clinically significant portal hypertension 
(CSPH). SSM reduction > 20% from baseline was defined 
as significant.
RESULTS
SSM significantly decreased at SVR24, in both patients 
with and without CSPH; in 44.8% of cases, SSM reduction 
was > 20%. LSPS significantly improved in the entire 
cohort at SVR24; SD and PLT changed significantly only 
in patients without CSPH. LSM significantly decreased 
in 65.7% of patients and also in 2/3 patients in whom 
SSM did not decrease. The independent predictor of 
decreased SSM was median relative change of LSM. 
CSPH persisted in 54.4% patients after SVR. Delta LSM 
and baseline SSM were independent factors associated 
with CSPH persistence.
CONCLUSION
SSM and other NITs significantly decrease after SVR, 
although differently according to the patient’s clinical 
condition. SSM faithfully reflects changes in portal 
hypertension and could represent a useful NIT for the 
follow-up of these patients.
Key words: Clinically significant portal hypertension; 
Spleen stiffness measurement; Advanced chronic liver 
disease; Direct-acting antivirals; Portal hypertension; 
Hepatitis C; Non-invasive test
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Liver stiffness measurement (LSM) and spleen 
stiffness measurement (SSM) are widely validated 
surrogates of portal hypertension (PH) and its complica-
tions. Their role in the assessment of therapy response, 
such as treatment with direct-acting antivirals (DAAs) 
of hepatitis C virus patients, is still under investigation. 
We demonstrated in a large cohort that not only LSM, 
but also SSM, is reduced six months after successful DAA 
therapy. As opposed to LSM, SSM directly reflects PH 
and is less influenced by the immediate reduction of liver 
necro-inflammation. We believe that SSM could represent 
a helpful tool for the clinician in the follow-up of these 
patients.
Ravaioli F, Colecchia A, Dajti E, Marasco G, Alemanni LV, Tamè 
M, Azzaroli F, Brillanti S, Mazzella G, Festi D. Spleen stiffness 
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INTRODUCTION
Chronic hepatitis C virus (HCV) infection represents 
one of the major causes of liver disease and is a lea­
ding cause of liver transplantation[1,2]. Recently, the 
introduction of the highly effective interferon­free direct­
acting antivirals (DAAs) has enormously increased the 
number of patients who have achieved sustained virologi­
cal response (SVR), even in patients with liver cirrhosis[3–5].
Studies, mostly from the interferon era, have shown 
that achieving SVR improves liver function[6,7], liver 
histology[8] and overall clinical outcomes[9]. However, the 
real impact of SVR in the DAA era, in terms of changes in 
portal hypertension (PH) and risk of decompensation on 
immediate follow­up, is not completely known, especially 
in patients with advanced chronic liver diseases (ACLD). 
PH is a progressive condition that represents a key point 
in the natural history of liver diseases[10]; therefore, its 
assessment by the hepatic venous pressure gradient 
(HVPG) measurement is fundamental in ACLD patients[11–
14]. Indeed, the development of clinically significant portal 
hypertension (CSPH) in patients with compensated ACLD 
(cACLD)[11] is highly associated with the risk of clinical 
decompensation events (ascites, variceal bleeding, 
jaundice and hepatic encephalopathy)[10].
To date, several studies have demonstrated a signi­
ficant reduction in HVPG (> 10%-20%) after achieving 
SVR, both after interferon­based[15–17] and DAA­based 
regimens[18–21]. Although the HVPG measurement is the 
gold standard to assess PH[11], it remains an invasive 
method[22] and its use is still limited only to highly spe­
cialized centres[12]; thus, its repeated measurements 
during the follow­up would hardly be applicable.
Consequently, many non­invasive tests (NITs) in 
the last decade, including liver and spleen stiffness 
measurements (LSM and SSM) as well as liver stiffness­ 
spleen diameter to platelet ratio score (LSPS), have 
been developed and validated to accurately assess 
PH degree and its complications[11,22–29]. In fact, the 
Baveno Ⅵ Consensus recently recommended that LSM 
values of 10 kPa should rule out cACLD patients, and 
values of 20­25 kPa should accurately identify CSPH 
in patients with viral hepatitis[11]. However, to date, 
few studies have evaluated the role of NITs in the PH 
assessment of SVR patients after DAA treatment, and 
their role in the follow­up. Even if most studies agree 
on the fact that LSM rapidly decreases after virus 
eradication[18,19,30–32], controversial data have emerged 
regarding the changes of SSM after SVR[30–32].
MATERIALS AND METHODS
Aims of the study
We aimed to: (1) investigate the possible effect of HCV­
DAA treatment on PH, evaluated by spleen stiffness 
changes as a mirror of PH; (2) as well as those of other 
NITs, after HCV­DAA treatment; moreover, we aimed 
to (3) identify the presence of predictors of the SSM 
changes in SVR patients after DAA therapy.
Study design and population
This is a retrospective analysis of prospectively collected 
data of HCV­related cACLD patients treated with DAAs 
between January 2015 and September 2017 at our 
department, with valid measurements of LSM and SSM 
by transient elastography (TE) at baseline (BL) and at 
six mo after the end of DAA treatment (SVR24).
According to the Baveno Ⅵ Criteria[11], values of 
LSM > 10 kPa at TE were considered suggestive of 
having cACLD; LSM cut­off ≥ 21 kPa was used to rule­
in CSPH, as previously described[33,34]. At baseline, 
laboratory values, Model for end­stage liver disease 
(MELD) and Child­Turcotte Pugh (CTP) scores were 
also reported for each patient.
We excluded patients who (1) had incomplete 
response to surgical resection or loco­regional ablation 
of previous HCC; (2) developed HCC during antiviral 
treatment; (3) developed variceal bleeding and/or 
endoscopic banding legation (EBL) during the study 
period; and (4) initiated or changed the dosage of 
non­selective beta­blockers (NSBB) or had portal vein 
thrombosis, transjugular intrahepatic portosystemic 
shunt (TIPS) and non­cirrhotic PH. A subgroup of the 
patients who did not achieve SVR were separately 
investigated. 
Antiviral treatment
Eligibility for treatment of HCV patients with DAAs was 
assessed following the priority criteria established in 
the protocol approved by the Italian Medicines Agency 
committee. The choice of DAA and treatment duration 
(12 or 24 wk) was based on viral genotype and stage 
of disease, according to the guidelines available at the 
time of enrollment[35]. SVR was defined as undetectable 
HCV­RNA using real­time PCR, with a detection limit of 
15 IU/mL at the 12­wk post­treatment follow­up visit.
NITs for PH assessments
LSM values were assessed by expert operators using 
the FibroScan® apparatus with “M” probe (Echosens®, 
Paris, France) after overnight fasting and after a com­
plete abdominal US examination. LSM values were 
obtained as previously reported[16], and the reliability 
criteria considered were according to the last EFSUMB 
Guidelines and Recommendations on the Clinical Use of 
Ultrasound Elastography[36]. SSM was assessed on the 
same day as LSM assessment, with the same probe 
utilized to perform LSM using the FibroScan® apparatus, 
as previously described[24]. Since no specific literature 
is present, we translated data from HVPG experience[11] 
and defined significant SSM as a reduction > 20% from 
BL. LSPS was calculated as liver stiffness × (spleen 
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diameter (SD)/platelet count)[37]. SD was considered to 
be the bipolar diameter of the spleen as assessed by 
ultrasound.
Statistical analysis
Categorical data are expressed as numbers (percen­
tages) and continuous variables as medians (IQR or 
range). For group comparison, the Mann­Whitney U test 
was used for continuous variables and the chi2 test for 
categorical variables. Group comparisons among NITs 
at BL and SVR24 were evaluated with Friedman’s non­
parametric test, and Bonferroni­corrected alphas were 
used for post hoc pairwise comparison. Demographic, 
clinical, functional and elastometric variables were 
evaluated with univariate and multivariate Logistic 
Regression models in order to assess the predictive 
factors associated with PH improvement as assessed 
by SSM. After evaluation of multicollinearity, variables 
with a p­value < 0.10 upon univariate analysis were 
included in several multivariate Logistic Regression 
models with stepwise backward procedures. Prevalence 
of esophageal varices (EV) was not included in the 
multivariate analysis due to the limited number of 
patients with available EGD data (within 6 mo from 
TE assessment). The estimated odds ratios with their 
95% confidence intervals, LR chi2 and Area under ROC 
Curve were presented. For each multivariable logistic 
regression, the model discrimination and calibration 
were reported together with Akaike information crite­
rion and Bayesian information criterion measures for 
comparing maximum likelihood models. Only p­values 
< 0.05 were considered statistically significant. The 
statistical analysis was conducted using Stata/SE (Ver­
sion 14.0; Stata Corp, Texas, United States).
Ethics
The DAAs treatment protocol was approved by the 
National Institutional Review Board (IRB) of the Italian 
Medicines Agency committee. Local IRB [Institutional 
Ethics Committee of Sant’Orsola­Malpighi University 
Hospital (Bologna, Italy)] approval was authorized.
RESULTS
Patients characteristics
One hundred­ninety­seven cACLD patients treated 
with DAAs and with available valid baseline LS and SS 
measurements were evaluated. The following patients 
were excluded: two (1%) had HCC occurrence and 
three (1.5%) presented with active HCC, one (0.5%) 
underwent EBL during the study period, four (2%) 
had previous EBL, two (1%) patients presented with 
complete portal vein thrombosis, one (0.5%) required 
an increase in NSBB dosage and one (0.5%) had 
previous TIPS placement. An additional 37 (18.8%) 
patients were excluded: 22 (out of 197, 11.2%) due 
to lack of follow-up and 15 (out of 197, 7.6%) due to 
unfeasible SSM at follow­up. Accordingly, a total of 134 
Ravaioli F et al . Spleen stiffness measurement and PH after DAAs
patients with paired LSM and SSM at BL and SVR24 
were included in the final analysis; 12 (6%) patients 
who did not achieve SVR were analysed separately 
(Figure 1). 
Table 1 depicts the baseline characteristics of the 
study cohort. Regarding main NITs, the median values 
at BL were LSM 19.3 kPa (14.1­27 kPa) and SSM 58.8 
kPa (42.2­75 kPa). In a sub­analysis, patients with 
CSPH (LSM ≥ 21 kPa) differed significantly for MELD 
score, platelet count, total serum bilirubin, INR, SSM, 
LSM, SSM and LSPS. 
Changes in SSM and LSM after SVR
In the patients who achieved SVR, the median SSM 
significantly decreased from 58.8 kPa to 38.2 kPa 
(p = 0.001), with a median delta change in SSM 
of – 12.3%. The decrease in SSM was statistically 
significant in both groups, CSPH and not (Figure 2A); 
the median delta SSM was higher in patients without 
CSPH at baseline when compared to patients with 
CSPH (-20.4% vs -4.7%), although this difference did 
not reach statistical significance. A decrease in SSM 
values was found in 92 (68.7%) patients, of whom 
73 (54.5%) had a decrease > 10% and 60 (44.8%) 
> 20% (Table 2 and Figure 3A). LSM values also 
decreased after SVR, with respective median values 
of 19.3 kPa and 13.8 kPa at baseline and SVR24 (p < 
0.0001). The median delta LSM was -30% with similar 
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changes in both groups; LSM decreased in 114 (85.1%) 
patients, of whom 88 (65.7%) had a decrease of > 
20% (Table 2 and Figure 3A). 
A LSM decrease was found in almost all patients in 
whom SSM decreased (95.3%). On the other hand, 
LSM significantly decreased (p = 0.022) in 2/3 of the 
patients in whom SSM did not decrease, with a median 
delta LSM of -28.3%. (Figure 3B). 
Changes in other NITs after SVR
The median spleen diameter (SD) at baseline and 
SVR24 were 14 cm and 13.2 cm, respectively. Althou­
gh the reduction was not statistically significant in 
the overall population, it reached significance in the 
subgroup of patients without CSPH. The increase of 
PLT (from 110 109/L to 130 109/L) did not reach stati­
stical significance in the entire cohort either, but only in 
patients without CSPH (Figure 2B). Moreover, median 
LSPS differed significantly between baseline (2.78) and 
SVR (1.34), and in both subgroups as well.
Non-SVR patients
Twelve patients did not achieve SVR in our cohort. 
Baseline characteristics did not statistically differ from 
the patients included in the final analysis. In particular, 
in non­SVR patients, an LSM decrease (23.2 kPa at BL 
vs 21.6 kPa at FU24), an SSM increase (45.6 kPa at 
BL vs 57.8 kPa at FU24) and a PLT decrease (128 × 
Figure 1  Flowchart of study design. DAA: Direct-acting antiviral; EBL: Endoscopic band ligation; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; LSM: 
Liver stiffness measurement; NSBB: Non-selective beta-blocker; SSM: Spleen stiffness measurement; SVR: Sustained virological response; TIPS: Transjugular 
intrahepatic portosystemic shunt.
HCV-patients treated with DAAs
regimens with LSM > 10 kPa and
available SSM at baseline n  = 197
Patients with HCC occurrence during study
period or active previous HCC (n  = 5)
Patients who developed variceal bleeding or
underwent EBL during study period (n  = 1)
Patients with previous EBL, NSBB 
initiation/change of dosage, portal vein 
thrombosis, TIPS or non-cirrhotic portal 
hypertension (n  = 8)
Patients lost at follow-up (n  = 22)
Patients with unfeasible SSM at follow-up visit 
(n  = 15)
Included patients with paired LSM 
and SSM before and 6 mo after SVR 
n  =134
Included patients who did not 
achieve SVR 
n  =12
Ravaioli F et al . Spleen stiffness measurement and PH after DAAs
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109/L at BL vs 100 × 109/L at FU24) were observed; 
none of these changes reached statistical significance 
(Supplementary Table 1).
Predictors of significant SSM Decrease (> 20%)
Table 3 shows the differences observed between 
patients who had an SSM decrease > 20% and those 
who did not. In the entire cohort, patients with sig­
nificant SSM reduction differed in the prevalence of 
EV, MELD score, albumin levels, as well as baseline 
SSM, LSPS values and LSM­related variables. In 
multivariate analysis, relative LSM changes remained 
as the only independent predictor of an SSM decrease 
> 20%. Furthermore, predictors of an SSM decrease 
> 20% (Supplementary Table 2) were investigated 
among patients with CSPH at baseline. Once again, 
a higher prevalence of EV, higher creatinine levels, 
lower LSM values at SVR24 and higher delta LSM were 
observed among patients with an SSM decrease > 
20%. In multivariate analysis, higher serum creatinine 
levels and delta LSM > 20% were the predictors of a 
significant SSM decrease. 
Changes of CSPH state after SVR
Figure 4 shows that 60 (44.8%) patients presented 
with CSPH at baseline, defined as an LSM ≥ 21 kPa. 
After a 6 mo follow­up, none of the 74 patients without 
CSPH at baseline progressed to CSPH. In patients with 
CSPH, 46.7% of them had reduced LSM under the 
CSPH threshold after treatment. Supplementary Table 
3 shows the predictors of CSPH persistence after DAA 
treatment. 
DISCUSSION
The main aim of our study was to evaluate PH changes 
assessed by non­invasive methods after successful 
viral eradication in patients treated with DAAs. Our 
data show that SSM and LSM significantly decrease 
after SVR, according to the baseline clinical patient 
condition. 
The IFN­free regimens are highly effective, allowing 
to treat and achieve SVR in patients who also have 
ACLD[4,38]. However, the individual clinical benefit in 
these patients is still under debate, especially in terms 
of changes in PH and CSPH­driven complications[39–41]. 
While results from the interferon era might not nece­
ssarily be translatable to DAA regimens[21], recent stu­
dies have also unanimously demonstrated that HVPG 
significantly decreases after SVR[18–21]. Although many 
Qualitative data were expressed as number and percentage (%); quantitative data were expressed as median (25%-75% quantiles). ALT: Alanine 
aminotransferase; AST: Aspartate aminotransferase; CSPH: Clinically significant portal hypertension; DCV: Daclatasvir; HRV: High risk varices; INR: 
International normalized ratio; LDV: Ledipasvir; LSM: Liver stiffness measurement; LSPS: Liver stiffness to spleen/platelet score; MELD: Model for end-
stage liver disease; NITs: Non-invasive tests; RBV: Ribavirin; SMV: Simeprevir; SOF: Sofosbuvir; SVR: Sustained virological response; SSM: Spleen stiffness 
measurement.
Variable Overall (n  = 134) CSPH (LSM ≥ 21 kPa) (n  = 60) No CSPH (LSM < 21 kPa) (n  = 74)
Age (yr) 60 (51-69) 57 (50.5-65) 61.5 (51-70)
Male 92 (68.7) 42 (70) 50 (67.6)
HCV-genotype
   1 95 (70.9) 41 (68.3) 54 (72.5)
   2 12 (8.9) 4 (6.7) 8 (10.8)
   3 20 (14.9) 11 (18.3) 9 (12.2)
   4 7 (5.3) 4 (6.7) 3 (4.5)
Treatment regimen
   SOF/RBV 33 (24.6) 10 (16.7) 23 (31.1)
   SOF/SMV 29 (21.6) 15 (25) 14 (18.9)
   SOF/DCV 38 (28.4) 19 (31.6) 19 (25.6)
   SOF/LDV 16 (12) 7 (11.7) 9 (12.2)
   Other 18 (13.4) 9 (15) 9 (12.2)
Child Pugh Score
   A 115 (85.8) 52 (86.7) 63 (85.1)
   B 19 (14.2) 8 (13.3) 11 (14.9)
MELD Score 8 (7-10) 9 (8-10) 8 (7-10)
Spleen Diameter (cm) 14 (12.3-15.5) 14.7 (12.8-15.8) 13.9 (12.1-15)
Laboratory results
   Platelets (cells × 109/L) 110 (79-150) 102 (74-132) 134 (92-159)
   ALT (U/L) 58 (39-95) 55 (39-84) 60 (38-105)
   Bilirubin (mg/dL) 0.9 (0.67-1.29) 1 (0.84-1.52) 0.8 (0.6-1.1)
   Albumin (g/dL) 3.8 (3.6-4.1) 3.8 (3.5-4.1) 3.8 (3.6-4.1)
   Creatinine (mg/dL) 0.8 (0.7-0.98) 0.8 (0.70-0.96) 0.85 (0.71-1.08)
   INR 1.1 (1.06-1.2) 1.17 (1.1-1.21) 1.08 (1.04-1.13)
NITs
   SSM (kPa) 58.8 (42.2-75) 69.9 (55.7-75) 46.2 (31.6-63.9)
   LSM (kPa) 19.3 (14.1-27) 29.1 (23.9-39.7) 14.6 (12-17)
   LSPS 2.78 (1.4-4.94) 5.1 (3.05-7.48) 1.58 (1.09-2.79)
Table 1  Baseline characteristics of included patients
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studies have shown that LSM rapidly decreases after 
DAA treatment[42,43], not much is known about the 
changes of PH surrogate NITs, such as SSM and LSPS, 
after viral eradication. In fact, NITs have yet to be 
validated in SVR patients, and their role in the clinical 
follow­up is still to be determined. 
The main finding of this study is that SSM signi­
ficantly changes after 24 wk of SVR in patients with 
cACLD, with a median relative change of -12.3% (Table 
2). To our knowledge, only two complete papers[30,32] 
and one letter to the editor[39] have investigated the 
changes in SSM after SVR, with opposing results. In 
fact, only in the study by Pons et al[32] SSM was found 
to rapidly decrease at only 4 wk after therapy initiation 
in 41 patients, with no ulterior significant changes until 
48 wk of follow­up; the other studies concluded that 
SSM did not significantly decrease at SVR24[30,32]. 
In our study that analyzed a large cohort of cACLD 
patients, we demonstrated that SSM significantly 
decreased after DAA treatment. These results confirm 
previous studies in which PH was assessed by paired 
HVPG measurements[18–21]. Moreover, our study is the 
first to assess and demonstrate the improvement of 
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LSPS, another accurate surrogate of PH, after SVR24. 
Moreover, in the eight patients who did not achieve 
SVR, SSM and other NITs did not significantly differ 
during follow­up measurements (Supplementary Table 1).
We classified patients with and without CSPH accor-
ding to a LSM cut­off of 21 kPa[33,34]. Interestingly, the 
relative changes in SSM and LSM performed differently 
in patients with and without CSPH. In fact, while the 
median delta LSM in patients with and without CSPH 
was very similar (-28.3% vs -30.8%), the reduction 
of SSM was much more evident in patients without 
CSPH (-20.4% vs -4.7%). This last result is consistent 
with the relative HVPG changes described by Mandorfer 
et al[18]. Moreover, the other surrogates of PH, including 
the platelet and spleen diameter, significantly chan­
ged only when split by CSPH presence. Regarding the 
different changes of NITs in patients with and without 
CSPH, we could speculate that this behaviour can 
reflect the different stages of underlying PH pathogenic 
mechanisms. Indeed, determinants of portal pressure 
affecting SSM, such as intrahepatic resistance and 
liver necro-inflammation[44], improve in both subgroups. 
However, in CSPH, other major actors of PH, such as 
Figure 2  Non-invasive tests changes after sustained viral response by clinically significant portal hypertension presence. A: LSM and SSM changes; B: PLT, 
SD, LSPS changes. CSPH: Clinically significant portal hypertension; LSM: Liver stiffness measurement; SSM: Spleen stiffness measurement; PLT:  Platelet count; 
SD: Spleen diameter; LSPS: Liver stiffness-to-spleen diameter-to-platelet count ratio score.
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extra­hepatic hemodynamic factors[34] and spleen stru­
ctural changes[45], might not ameliorate in the short­
term follow­up (6 mo after SVR). This hypothesis could 
explain why we found a less prominent SSM decrease 
(-4.7% vs -20.4%), even when liver necro-inflammation 
reduction as assessed by delta LSM (-28.3% vs -30.8%) 
was the same.
SSM reduction was present in 68.7% of patients 
after 6 mo of follow­up. We found that the only inde­
pendent predictor of a significant PH improvement, 
as reflected by a SSM decrease > 20%, was the 
relative change in LSM (Table 3), confirming previous 
studies with HVPG[18,21]. However, when we assessed 
PH improvement as reflected by SSM in our study, as 
PH surrogate, and by HVPG in the study by Lens et 
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al[21], we noticed similar proportions of patients with a 
significant response (> 20%) when comparing SSM and 
HVPG (38.3% vs 39.8%, respectively), but not LSM 
and HVPG (66.7% vs 39.8%, respectively) (Figure 3A). 
Even if a correlation between HVPG and SSM changes 
after DAA treatment has not been demonstrated to 
date, our data may suggest that an SSM reduction > 
20% could be a more accurate non-invasive predictor 
of a significant HVPG reduction[11].
A statement in the Baveno Ⅵ consensus was that 
the main therapeutic goal in patients with mild PH 
(6­9 mmHg) is to prevent CSPH development[11]. In 
our cohort, none of the patients who achieved SVR 
progressed to CSPH. More challenging, however, is the 
concept of assessment of CSPH presence/absence after 
SVR due to its clinical implications, since there is not 
sufficient evidence showing that the cut-offs after DAAs 
are the same as the ones used in the pre­treatment 
phase[23,46]. However, promising data documented 
that a LSM of 20­25 kPa could be an accurate cut­off 
to rule­in CSPH after DAA therapy[21]. Accordingly, we 
also investigated CSPH persistence after SVR (Figure 
4). Using these cut-offs, we found that 53% of the 
patients with CSPH at baseline presented CSPH at 
SVR24. In multivariate analysis, higher baseline values 
of SSM (indicating a more severe PH) and lower LSM 
relative changes were found to be predictors of CSPH 
persistence (Supplementary Table 3). These results 
are in line with another study[21] in which higher BL 
HVPG and relative LSM changes were predictors of 
CSPH persistence after DAA treatment. 
All of the above results seem to reflect the different 
dynamics in LSM and SSM changes after achieving SVR. 
LSM consensually decreased in almost all patients with 
SSM reduction (95.2%), while the opposite was not 
found to be true. In fact, LSM significantly decreased, 
with a median delta -28.3%, in 2/3 of the patients in 
whom no SSM reduction was found. This result empha­
sizes the fact that LSM is heavily influenced by the 
reduction of liver necro-inflammation[44] after SVR, and 
that changes in LSM might not be the most adequate 
predictors of PH changes in this context. On the other 
hand, a SSM decrease > 20% could identify patients 
who significantly clinically benefit from viral eradication. 
Figure 3  Spleen and liver stiffness measurement decreases after sustained 
viral response (A), and liver stiffness measurement decreases in patients 
without spleen stiffness measurement improvements (B). BL: Baseline; CSPH: 
Clinically significant portal hypertension; LSM: Liver stiffness measurement; 
SSM: Spleen stiffness measurement; SVR: Sustained virological response.
CSPH: Clinically significant portal hypertension; LSM: Liver stiffness measurement; PLT: Platelet count; SSM: Spleen stiffness measurement.
Table 2  Liver and Spleen stiffness measurement decreases after sustained viral response
Variable Overall (n  = 134) CSPH (LSM ≥ 21 kPa) (n  = 60) No CSPH (LSM < 21 kPa) (n  = 74)
Relative SSM decrease (%) 12.3 (0-36.3) 4.7 (0-32.5) 20.4 (0-39.7)
Overall SSM decrease 92 (68.7) 40 (66.7) 52 (70.3)
   > 10% 73 (54.5) 31 (51.7) 42 (56.8)
   > 20% 60 (44.8) 23 (38.3) 37 (50)
Relative LSM decrease (%) 30 (13.5-42.4) 28.3 (11.4-41.9) 30.8 (13.9-42.4)
Overall LSM decrease 114 (85.1) 51 (85) 63 (85.1)
   > 10% 108 (80.6) 48 (80) 60 (81.1)
   > 20% 88 (65.7) 40 (66.7) 48 (64.9)
PLT Increase (%) 12.4 (-10.1 to 29.6) 5.5 (-15.6 to 25.9) 17.4 (-0.67 to 35.6)
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Agency committee eligibility criteria for the treatment 
of HCV patients with DAAs, and (2) the absence of a gold­
standard reference for PH assessment. However, accor­
ding to the Baveno Ⅵ consensus[11], we could consider 
NITs, in addition to LSM, to be good surrogates of invasive 
methods, such as liver biopsy and HVPG. The time of 
follow­up was too short to fully correlate SSM changes with 
clinical outcomes after viral eradication, such as events of 
decompensation after SVR[48]. As in previous studies that 
include SSM, the upper limit of 75 kPa for SSM affects 
the possibility to detect changes in patients with severe 
PH[49,50]; in fact, both BL and SVR24 values were 75 kPa 
in seven (5.2%) patients.
In conclusion, SSM could be an accurate and use­
ful NIT for the follow­up of patients after SVR, as it 
faithfully reflects changes in PH better than other NITs, 
including LSM. Further prospective studies are required 
in order to confirm the accuracy and usefulness of SSM 
and other NITs in the follow­up of patients with ACLD 
and its correlation with clinical outcomes.
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Research background
The long-term benefits of achieving sustained virological response (SVR) in 
cirrhotic patients are still to be established. Non-invasive tests (NITs), such 
Figure 4  Clinically significant portal hypertension presence, according to 
Baveno Ⅵ (liver stiffness measurement ≥ 21 kPa) at baseline and after 
SVR24. CSPH: Clinically significant portal hypertension; LSM: Liver stiffness 
measurement; SSM: Spleen stiffness measurement; SVR: Sustained virological 
response.
Qualitative data were expressed as number and percentage (%); quantitative data were expressed as median (25%-75% quantiles). AIC: Akaike information 
criterion; ALT: Alanine aminotransferase; AUROC: Area under curve ROC; AST: Aspartate aminotransferase; BIC: Bayesian information criterion; CSPH: 
Clinically significant portal hypertension; DCV: Daclatasvir; HRV: High risk varices; INR: International normalized ratio; LDV: Ledipasvir; LR: Like-hood 
ratio; LSM: Liver stiffness measurement; LSPS: Liver stiffness to spleen/platelet score; MELD: Model for end-stage liver disease; NITs: Non-invasive tests; 
RBV: Ribavirin; SMV: Simeprevir; SOF: Sofosbuvir; SVR: Sustained virological response; SSM: Spleen stiffness measurement.
Table 3  Univariate and multivariate analysis of factors associated with a SSM decrease > 20%
Entire Population (n  = 134)
Variable
Univariate analysis
Multivariate analysis
LR Chi-2 = 16.48 AIC = 171.8
AUROC = 0.6821 BIC = 177.6
SSM Decrease > 
20% (n  = 60)
No SSM Decrease > 
20% (n  = 74) OR (95%CI) P  value OR (95%CI) P  value
Age (yr) 62 (52-69) 56 (50-68) 1.005 (0.975-1.037)   0.727
Sex (male) 21 (28.4) 21 (35) 1.359 (0.653-2.828)   0.412
Presence of varices (n = 67) (yes) 9 (34.2) 24 (82.8) 0.110 (0.031-0.388)   0.001
Spleen diameter (cm) 13.6 (11.65-15.15) 14.5 (13-16) 0.800 (0.660-0.970)   0.023
Child Pugh Score 5 (5-6) 5 (5-6) 0.885 (0.601-1.303)   0.535
Child Pugh Score B (yes) 8 (13.3) 11 (14.9) 0.881 (0.330-2.352)   0.801
MELD score 8 (7-10) 9 (8-10) 0.786 (0.648-0.954)   0.015
MELD > 10 12 (20) 30 (40.5) 0.367 (0.167-0.804)   0.012
AST (U/L) 54.5 (38-85) 56 (35.5-87) 0.996 (0.987-1.004)   0.322
ALT (U/L) 62 (37-105) 53 (40-90) 1.002 (0.995-1.008)   0.620
ALT ≥ 2 × ULN at BL 59.5 (37.5-101) 54 (40-91.5) 1.326 (0.597-2.944)   0.489
INR 1.09 (1.05-1.17) 1.12 (1.09-1.21) 0.127 (0.001-0.551)   0.023
Bilirubin (mg/dl) 0.85 (0.65-1.16) 1.02 (0.71-1.52) 0.903 (0.535-1.525)   0.703
Albumin (g/dl) 3.8 (3.52-4.12) 3.78 (3.52-4.12) 2.096 (0.959-4.581)   0.063
Creatinine (mg/d) 0.8 (0.7-1) 0.81 (0.69-0.93) 0.327 (0.674-1.585)   0.165
Platelet count (10^9/L) 118 (92-154) 91 (74-137) 1.002 (0.996-1.007)   0.579
LSM BL (kPa) 18 (14.6-25.7) 21.1 (14-38.5) 0.988 (0.962-1.015)   0.391
LSM SVR24 (kPa) 12.4 (9.4-18) 17.5 (10.4-32.4) 0.944 (0.908-0.981)   0.004
SSM BL (kPa) 60.4 (45.7-70.7) 53.2 (37.4-75) 1.012 (0.992-1.032)   0.225
LSPS BL 2.17 (1.33-3.77) 4.15 (1.65-6.26) 0.817 (0.684-0.975)   0.025
LSM decrease (Delta, %) 33 (18.1–44.6) 19.4 (0–31.3)   0.0332 (0.005-0.225) < 0.0001 0.0332 (0.005-0.225) < 0.0001
LSM decrease > 10% (yes) 54 (90) 54 (73) 3.333 (1.242-8.946)   0.017
LSM decrease > 20% (yes) 47 (78.3) 41 (55.4) 2.910 (1.352-6.262)   0.006
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When looking at the bigger picture, SSM could represent 
a feasible tool to monitor therapy response and assess 
its benefit. This is also supported by a recent study 
by Buechter et al[47] that investigated LSM and SSM 
changes after TIPS placement. 
The present study has some limitations: (1) its retro­
spective nature, even though SSM and LSM were pros­
pectively collected according to the Italian Medicines 
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as liver (LSM) and especially spleen stiffness (SSM), are widely validated in 
hepatology as portal hypertension (PH) surrogates. However, their use in SVR 
patients and their changes after virus eradication is still under discussion.
Research motivation
Many studies have reported rapid LSM decrease after achieving SVR. However, 
only a few have investigated changes in SSM in such patients, with contrasting 
results. Given that there is a decrease in SSM after therapy, it means that SSM 
could be exploited to assess changes in PH and PH-driven complication after 
achieving SVR. 
Research objectives
The main objective of the study was to investigate changes in PH after success-
ful eradication of HCV infection, as reflected by its non-invasive assessment by 
SSM and other NITs.
Research methods
This is a retrospective study of prospectively collected data. Patients with 
available paired SSM assessment at baseline and 6 mo after end-of-therapy 
(SVR24) were included in the study.
Research results
Our main result is that a significant SSM decrease at SVR24 was demonstrated 
in a large cohort of 134 patients. This is the first study that also reveals a 
decrease in LSPS after SVR. SSM reduction differed according to the patient’s 
clinical condition, especially when divided by the presence of clinically signi-
ficant PH. An LSM decrease of > 20% was evident in the majority of patients, 
and also in patients in whom no SSM reduction was present. This finding likely 
reflects the reduction in liver necro-inflammation rather than PH improvement.
Research conclusions
PH, reflected by NITs, improves after achieving SVR in cirrhotic patients. SSM 
is a direct surrogate of PH and less influenced by liver necro-inflammation, as 
opposed to LSM. Its decrease (> 20%) could help the clinician to stratify the risk 
for PH-related complication after DAA therapy.
Research perspectives
Future prospective studies should investigate whether changes in SSM are 
predictive of clinical decompensation or other complications of cirrhosis after 
viral eradication. SSM could become a helpful and accurate method to assess 
therapy response and the risk of complications.
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